Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases
Last Updated: Friday, January 28, 2022
Patients with small and non–small cell lung cancer with bone metastases receiving extended interval dosing with zoledronic acid experienced comparable incidence and time to skeletal-related events as patients receiving standard dosing, according to data from a recent retrospective trial.
Advertisement
News & Literature Highlights